Beasley Allen attorney Rhon Jones outlines criteria for BP Oil Spill claims

| Toxic Exposure, Environmental Disasters

On this week’s episode of The Beasley Allen Report, Beasley Allen attorney Rhon Jones provides information about how any business in Alabama may qualify for compensation under the BP Oil Spill settlement. He talks with guest host and Beasley Allen lawyer Parker Miller, who is filling in for the show’s regular host Gibson Vance. Miller works in the firm’s Toxic Torts section alongside Jones, handling BP claims. Jones, who serves on the Plaintiffs Steering Committee for the multidistrict litigation, terms the BP settlement as “probably the most unique class-action settlement in the history of American litigation.” The settlement was reached in March-April 2011, with approximately $2 billion already paid or approved to be paid within not quite three years of the date of the oil spill. “Businesses all over this state were impacted. Individuals all over this state were impacted,” by the BP Oil Spill, Jones says. He outlines how businesses in particular can file a claim and find out if their losses qualify under the terms of the settlement, and how to maximize their claim. “The good news here is almost every business in the state is eligible [for compensation]. Everyone can participate if they feel like they have a loss,” he said.

Rhon Jones

Rhon heads the Toxic Torts Section and oversees nursing home abuse and neglect cases.

We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.

Continuing the battle with Big Pharma

The entire Beasley Allen staff had our personal interest at heart. We were part of the family of a down to earth, trustworthy, understanding law firm. Thank you, Beasley Allen, for continuing the battle with Big Pharma.